Back to Search Start Over

Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine.

Authors :
Dong N
Yu J
Wang C
Zheng X
Wang Z
Di L
Song G
Zhu B
Che L
Jia J
Jiang H
Zhou X
Wang X
Ren J
Source :
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2012 Jul; Vol. 138 (7), pp. 1197-203. Date of Electronic Publication: 2012 Mar 17.
Publication Year :
2012

Abstract

Purpose: Docetaxel plus capecitabine, a commonly used chemotherapeutic regimen for metastatic breast cancer (MBC), is highly variable in its effectiveness. We aimed to investigate whether allelic variants of cytochrome P450 (CYP450) affected objective response, progression-free survival (PFS), and overall survival (OS) in MBC.<br />Patients and Methods: 79 SNPs in CYP450, whose minor allele frequency were ≥ 10%, were genotyped in 69 MBC patients who were treated with docetaxel plus capecitabine. Pearson's χ(2) test or Fisher's exact test was used to investigate the influence of SNPs on objective response as appropriate. Log-rank test was used to assess the association between SNPs and survival outcomes.<br />Results: There is no significant association between polymorphisms and both objective response and OS. Only one SNP, CYP1A1 rs1048943 A>G (Ile462Val), was significantly associated with PFS (P = 0.0003). Multivariate analysis confirmed its prognostic significance for PFS (P = 0.004).<br />Conclusion: CYP1A1 rs1048943 A>G (Ile462Val) polymorphism is a potential prognostic marker for survival outcome after docetaxel plus capecitabine chemotherapy in MBC patients. However, confirmatory study is needed to validate this finding.

Details

Language :
English
ISSN :
1432-1335
Volume :
138
Issue :
7
Database :
MEDLINE
Journal :
Journal of cancer research and clinical oncology
Publication Type :
Academic Journal
Accession number :
22426923
Full Text :
https://doi.org/10.1007/s00432-012-1183-5